December 2019 Briefing – Diabetes & Endocrinology
Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for December 2019. This roundup includes...
APO(a)-LRX Found to Reduce Lipoprotein(a) Levels
Dose-dependent reduction found in patients with elevated lipoprotein(a) levels, cardiovascular disease
MIV-711 No Better Than Placebo for Pain Relief in Knee OA
But significant reductions seen in medial femoral bone area progression, medial femoral cartilage thinning
Machine Learning System Makes More Alerts for Med Errors
68.2 percent of MedAware alerts would not have been generated with clinical decision support system
Gastric Sleeve Tied to Lower Risk for Subsequent Procedures
But rates of bariatric conversion, revision procedures higher for gastric sleeve versus gastric bypass
Poor Diet Contributes Substantially to Cardiometabolic Disease Costs
Diet tied to more than $50 billion in annual health care costs for heart disease, stroke, diabetes
High Lipoprotein(a) Is Risk Factor for CVD in Type 1 Diabetes
Lp(a) significant risk factor for macrovascular disease, albuminuria, calcified aortic valve disease
Inflammation Linked to Thyroid Dysfunction in Psoriasis Patients
Patients with thyroid dysfunction and psoriasis have higher serum C-reactive protein levels
Multiple Health Benefits Reported for Intermittent Fasting
Review suggests health benefits can be attributed to more than just reduction in caloric intake
Liposuction Benefits Women With Lipedema
Most wait years for diagnosis and have other health issues, often an underactive thyroid gland
